Asset
Verekitug
Upstream Bio Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05448651 | phase1 | completed | 2022-07-08 | 2023-08-15 | Upstream Bio Inc. | Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
| NCT05653479 | phase1 | completed | 2022-12-05 | 2023-04-07 | Upstream Bio Inc. | Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults |
FDA applications (0)
This company has no applications containing this asset.